

Figure 1.1 Current treatment options of osteoporosis and their drawbacks	3
Figure 2.1 Current treatment options of osteoporosis and their drawbacks	15
Figure 2.2 Schematic presentation of different phases of cationic lipid complexes with NA (nucleic acid) observed with different neutral lipids at different molar fractions. Lamellar phase (L_{α}^{NA}): NA is adhered to in a monolayer fashion on the surface of the bilayered lamella, inverted hexagonal phase (H_{II}^{NA}) : NA molecules surrounded by inverted cylindrical micelles and gyroid cubic phase ($Q_{II}^{G,NA}$) : water channels (shown in orange and green)containing NA molecules surrounded by lipid bilayers (shown as grey sheet which represents the lipid bilayer as shown in enlarged inset).....	27
Figure 2.3 Schematic structures of lipoplex, lipopolyplex and lipid nanoparticle based NA delivery systems.....	29
Figure 2.4 Schematic structures of micelles, solid lipid nanoparticle and nanoemulsion based NA delivery systems.....	29
Figure 2.5 (A) Transfection efficiency as a function of mole fraction of DOPC and cationic lipids (B) Transfection efficiency as a function of membrane charge density. Color legends: Different lipids evaluated are shown in different colour legends i.e. DOTAP – monovalent (grey circles for DOTAP-DOPC system and open grey circles for DOTAP-DOPE system), MVL2 - divalent (green diamonds), MVL3 - trivalent (red squares), MVL5 - pentavalent (blue triangles) and TMVL5 - pentavalent (purple inverted triangles). Gaussian fit to the DOPC systems is shown as a bell shaped curve which is divided in three regimes of transfection efficiency by grey and white shading.	38
Figure 3.1 UV absorption profile of isolated pDNA	57
Figure 3.2 Correlation of actual concentration of pDNA vs observed concentration.....	58
Figure 3.3 Agarose gel.....	60
Figure 3.4 Agarose gel electrophoresis unit.....	62
Figure 3.5 Determination of quantifiable range of pDNA.....	62
Figure 3.6 Band densities at 200 ng Lane 1 to Lane 6: 200 ng pDNA.....	63
Figure 3.7 Gel electrophoresis band densities at different pDNA concentrations.....	64
Figure 3.8 Band densities determined using ImageJ software.....	65
Figure 3.9 Calibration plot of DNA gel retardation.....	66
Figure 3.10 Reaction of primary amine containing compound with TNBS.....	67
Figure 3.11 Overlay spectra of TNBS assay for stearyl amine.....	69

Figure 3.12 Calibration curve of TNBS assay of stearyl amine	69
Figure 3.13 Effect of incubation time on linearity of method and response at 340 nm absorbance for TNBS assay of stearyl amine	70
Figure 3.14 Overlay spectra of TNBS assay of DOPE A) Left panel→1 hr reaction time B) Right panel→ 6 hr reaction time.....	72
Figure 3.15 Effect of incubation time on linearity of method and response at 340 nm absorbance for TNBS assay of DOPE	73
Figure 3.16 Overlay spectra of TNBS assay of DSPE A) Left pane→1 hr reaction time B) Right panel→ 6 hr reaction time.....	74
Figure 3.17 Calibration curve of TNBS assay of DSPE at 340 nm.....	75
Figure 3.18 Overlay spectra of Sakaguchi assay of Boc-arginine (X-axis: Absorbance, Yaxis: wavelength (nm)).....	77
Figure 3.19 Calibration curve of Sakaguchi assay of Boc-arginine	77
Figure 4.1 Cloning and restriction digestion sites of BMP-9 pDNA.....	87
Figure 4.2 Schematic diagram representing the streaked agar plates with different E. Coli	93
Figure 4.3 Flow chart representing the alkaline lysis and isolation method of Qiagen kit.	96
Figure 4.4 Chemical structures of the Qiagen anion exchange resin and DNA showing their respective binding sites.....	97
Figure 4.5 Restriction Digestion of BMP-9 pDNA by HindIII and XhoI enzyme.....	103
Figure 4.6 Restriction digestion of eGFP pDNA by HindIII enzyme	103
Figure 5.1 Synthesis of histidine conjugated stearyl amine.....	108
Figure 5.2 Synthesis of Boc-carnosine	109
Figure 5.3 Structure of stearyl amine and stearyl amine based lipids (Value at amine groups indicates the calculated pKa of that group according to Chemaxon (Chemicalize.org)).....	113
Figure 5.4 Structure of Histidine and carnosine modified DOPE and DSPE.....	114
Figure 5.5 UV spectra of stearyl amine, Boc-histidine and Boc-His-SA (x-axis: wavelength, y-axis: absorbance).....	116
Figure 5.6 UV spectra Carnosine and carnosine isolated after Boc protection (x-axis: wavelength, y-axis: absorbance).....	117
Figure 5.7 NMR spectra of Carnosine and Boc-Carnosine	117

Figure 5.8 IR spectra of Carnosine and Boc-Carnosine	118
Figure 5.9 UV spectra of stearyl amine, Boc-His and Boc-His-SA (x-axis: wavelength, y-axis: absorbance).....	118
Figure 5.10 UV spectra of stearyl amine, Boc-Car and Boc-Car-SA (x-axis: wavelength, y-axis: absorbance)	119
Figure 5.11 UV spectra of DOPE, Boc-histidine and Boc-His-DOPE (x-axis: wavelength, y-axis: absorbance)	119
Figure 5.12 UV spectra of DOPE, Boc-Car and Boc-Car-DOPE (x-axis: wavelength, y-axis: absorbance).....	120
Figure 5.13 UV spectra of DSPE, Boc-His and Boc-His-DSPE (x-axis: wavelength, y-axis: absorbance).....	120
Figure 5.14 pH titration curve of Boc-Histidine, Boc-His-SA and His-SA	122
Figure 5.15 pH titration curve of Carnosine, Boc-Carnosine, Boc-Car-SA and Car-SA	122
Figure 5.16 pH titration curve of DOPE, His-DOPE and Car-DOPE	123
Figure 5.17 pH titration curve of DSPE and His-DSPE	123
Figure 6.1 Structure of 1) stearyl amine (Value at amine/carboxylic acid groups indicates the calculated pKa of that group according to Chemaxon Chemicalize.org)	113
Figure 6.2 Structure of Histidine and carnosine modified DOPE and DSPE.....	114
Figure 6.3 Lyophilization Cycle	116
Figure 6.4 Temperature Change during Lyophilization	117
Figure 6.5 Intensity-weighted particle size distribution of Batch S1.....	127
Figure 6.6 Intensity-weighted particle size distribution of Batch S2.....	127
Figure 6.7 Intensity-weighted particle size distribution of Batch S3.....	127
Figure 6.8 Intensity-weighted particle size distribution of Batch S4.....	128
Figure 6.9 Intensity-weighted particle size distribution of Batch S5.....	128
Figure 6.10 Intensity-weighted particle size distribution of Batch S6.....	128
Figure 6.11 Intensity-weighted particle size distribution of Batch S7.....	129
Figure 6.12 Intensity-weighted particle size distribution of Batch S8.....	129
Figure 6.13 Intensity-weighted particle size distribution of Batch S9.....	129
Figure 6.14 Intensity-weighted particle size distribution of Batch S10.....	130
Figure 6.15 Intensity-weighted particle size distribution of Batch S11.....	130
Figure 6.16 Intensity-weighted particle size distribution of Batch S12.....	130
Figure 6.17 Intensity-weighted particle size distribution of Batch S13.....	131

Figure 6.18 Intensity-weighted particle size distribution of Batch S14.....	131
Figure 6.19 Intensity-weighted particle size distribution of Batch S15.....	131
Figure 6.20 Intensity-weighted particle size distribution of Batch S16.....	132
Figure 6.21 Intensity-weighted particle size distribution of Batch S17.....	132
Figure 6.22 Intensity-weighted particle size distribution of Batch S18.....	132
Figure 6.23 Intensity-weighted particle size distribution of Batch S19.....	133
Figure 6.24 Intensity-weighted particle size distribution of Batch S20.....	133
Figure 6.25 TEM image of SA liposomes of Batch S13	133
Figure 6.26 TEM image of S+A liposomes of Batch S16	134
Figure 6.27 TEM image of liposomes of Batch S19	134
Figure 6.28 TEM image of liposomes of Batch S20	135
Figure 6.29 Intensity-weighted particle size distribution of PEGylated (Red) and Non-PEGylated (Green) SA liposomes	139
Figure 6.30 Intensity-weighted particle size distribution of HSA liposomes (Red) and BHSA liposomes (Green)	140
Figure 6.31 Intensity-weighted particle size distribution of BCSA liposomes (Red) and CSA liposomes (Green)	140
Figure 6.32 Intensity-weighted particle size distribution of ASA liposomes (Red) and BASA liposomes (Green)	140
Figure 6.33 Intensity-weighted particle size distribution of Batch D1	144
Figure 6.34 Intensity-weighted particle size distribution of Batch D2.....	144
Figure 6.35 Intensity-weighted particle size distribution of Batch D3.....	144
Figure 6.36 Intensity-weighted particle size distribution of Batch D4 repeat	144
Figure 6.37 Intensity-weighted particle size distribution of Batch D6.....	145
Figure 6.38 Intensity-weighted particle size distribution of Batch D7.....	145
Figure 6.39 Intensity-weighted particle size distribution of Batch D8.....	145
Figure 6.40 Intensity-weighted particle size distribution of Batch D9.....	145
Figure 6.41 Intensity-weighted particle size distribution of Batch D10.....	146
Figure 6.42 Intensity-weighted particle size distribution of Batch D11	146
Figure 6.43 Intensity-weighted particle size distribution of Batch D13.....	146
Figure 6.44 Intensity-weighted particle size distribution of Batch D14.....	146
Figure 6.45 Intensity-weighted particle size distribution of Batch D15.....	147
Figure 6.46 Intensity-weighted particle size distribution of Batch D15 repeat	147
Figure 6.47 Intensity-weighted particle size distribution of Batch D16.....	147

Figure 6.48 Intensity-weighted particle size distribution of Batch D17	147
Figure 6.49 Intensity-weighted particle size distribution of Batch D18	148
Figure 6.50 Intensity-weighted particle size distribution of Batch D20	148
Figure 6.51 Intensity-weighted particle size distribution of Batch D21	148
Figure 6.52 Intensity-weighted particle size distribution of Batch D22	148
Figure 6.53 Intensity-weighted particle size distribution of Batch D23	149
Figure 6.54 Intensity-weighted particle size distribution of Batch D24	149
Figure 6.55 TEM image of liposomes of Batch D3	149
Figure 6.56 TEM image of liposomes of Batch D8	150
Figure 6.57 TEM image of liposomes of Batch D11	150
Figure 6.58 TEM image of liposomes of Batch D22	151
Figure 6.59 Model diagnostic plots	157
Figure 6.60 Box-Cox plot of power transformation	158
Figure 6.61 Residual vs. factor plots for determining the time-independence of variance	159
Figure 6.62 Piepel's plot	160
Figure 6.63 Two-component mixture plots ; A: effect of HSPC and EPC, B: effect of HSPC and Chol, C: effect of EPC and Chol	161
Figure 6.64 Major lipid compositions of HSPC (A) and EggPC (B), DSPC-Distearoyl-sn- glycerophosphocholine, DPPC – Dipalmitoyl-sn-glycerophosphocholine and POPC, Palmitoyl oleoyl-sn-glycerophosphocholine	162
Figure 6.65 Contour plot of effects of different components on particle size	164
Figure 6.66 Response surface plot of effects of different components on particle size ...	164
Figure 6.67 Model diagnostic plots	167
Figure 6.68 Box-Cox plot of power transformation	169
Figure 6.69 Residual vs. factor plots for determining the time-independence of variance	170
Figure 6.70 Piepel's plot	171
Figure 6.71 Two-component mixture plots; A: effect of HSPC and EPC, B: effect of HSPC and Chol, C: effect of EPC and Chol	172
Figure 6.72 Contour plot of effects of different components on PDI	174
Figure 6.73 Response surface plot of effects of different components on PDI	174
Figure 6.74 Surface plots showing optimum particle size and PDI at best trade-off for the constraints	176

Figure 6.75 Desirability Plot for Selection of Optimized Batch.....	176
Figure 6.76 Design space with optimum response parameters.....	177
Figure 6.77 Intensity weighted particle size of His-DOPE liposomes	179
Figure 6.78 Intensity weighted particle size of Car-DOPE liposomes	179
Figure 6.79 Intensity weighted particle size of His-DSPE liposomes	179
Figure 6.77 Complexation efficiency of non-PEGylated SA lipoplexes – 30 min incubation.....	181
Figure 6.78 Complexation efficiency of non-PEGylated SA lipoplexes – 45 min incubation.....	182
Figure 6.79 Complexation efficiency of PEGylated SA lipoplexes 30 min incubation at 25°C	183
Figure 6.80 Complexation efficiency of PEGylated SA lipoplexes 45 min incubation at 25°C	183
Figure 6.81 Complexation efficiency of PEGylated SA lipoplexes 60 min incubation at 25°C	183
Figure 6.82 Complexation efficiency of PEGylated SA lipoplexes – 30 min incubation at 37°C	185
Figure 6.83 Complexation efficiency of PEGylated SA lipoplexes – 30 min incubation at 45°C	186
Figure 6.84 Complexation efficiency of Non-PEGylated SA lipoplexes	191
Figure 6.85 Complexation efficiency of PEGylated SA lipoplexes – 60 min incubation	192
Figure 6.86 Complexation efficiency of BHSA lipoplexes	192
Figure 6.87 Complexation efficiency of HSA lipoplexes.....	192
Figure 6.88 Complexation efficiency of BCSA lipoplexes	193
Figure 6.89 Complexation efficiency of CSA lipoplexes	193
Figure 6.90 Complexation efficiency of BASA lipoplexes	193
Figure 6.91 Complexation efficiency of ASA lipoplexes.....	194
Figure 6.92 TEM image of liposomes of SA lipoplexes	197
Figure 6.93 TEM image of liposomes of BHSA lipoplexes.....	198
Figure 6.94 TEM image of liposomes of HSA lipoplexes.....	198
Figure 6.95 TEM image of liposomes of BCSA lipoplexes	199
Figure 6.96 TEM image of liposomes of CSA lipoplexes.....	199
Figure 6.97 TEM image of liposomes of BASA lipoplexes.....	200
Figure 6.98 TEM image of liposomes of ASA lipoplexes.....	200

Figure 6.99 Complexation efficiency of HDO lipoplexes	202
Figure 6.100 Complexation efficiency of CDO lipoplexes	202
Figure 6.101 Complexation efficiency of HDS lipoplexes.....	203
Figure 6.102 Complexation efficiency of DOTAP/DOPE lipoplexes.....	203
Figure 6.103 TEM image of liposomes of HDO lipoplexes.....	206
Figure 6.104 TEM image of liposomes of CDO lipoplexes	206
Figure 6.105 TEM image of liposomes of HDS lipoplexes.....	207
Figure 7.1 Effect of electrolyte on particle size of the SA lipoplexes and non-PEGylated SA lipoplexes and DOTAP/DOPE lipoplexes	231
Figure 7.2 Effect of electrolyte on particle size of the SA, BCSA and CSA lipoplexes ..	231
Figure 7.3 Effect of electrolyte on particle size of the SA, BHSA and HSA lipoplexes..	232
Figure 7.4 Effect of electrolyte on particle size of the SA, BASA and ASA lipoplexes..	232
Figure 7.5 Effect of electrolyte on particle size of the SA, HDO, CDO and CDS lipoplexes	232
Figure 7.6 Effect of electrolyte on zeta potentials of the liposomes.....	234
Figure 7.7 Effect of electrolyte (2% NaCl) on complexation on efficiency of non-PEGylated and PEGylated SA lipoplexes at N/P ratio of 1.0 and 2.0 (200 ng pDNA/well)	237
Figure 7.8 Effect of electrolyte (2% NaCl) on complexation on efficiency of SA, BHSA and HSA lipoplexes at N/P ratio of 2.0 (200 ng pDNA/well)	238
Figure 7.9 Effect of electrolyte (2% NaCl) on complexation on efficiency of SA, BCSA and CSA lipoplexes at N/P ratio of 2.0 (200 ng pDNA/well)	238
Figure 7.10 Effect of electrolyte (2% NaCl) on complexation on efficiency of SA, BASA, ASA, HDO, CDO and CDS lipoplexes at N/P ratio of 2.0 (200 ng pDNA/well)	239
Figure 7.11 Serum stability of naked pDNA	242
Figure 7.13 Serum stability of lipoplexes (SA, BHSA and HSA) prepared at N/P ratio of 2 after incubation with serum	243
Figure 7.14 Serum stability of lipoplexes (BCSA and CSA) prepared at N/P ratio of 2 after incubation with serum.....	244
Figure 7.15 Serum stability of lipoplexes (BASA and ASA) prepared at N/P ratio of 2 after incubation with serum	244
Figure 7.16 Serum stability of lipoplexes (HDO, CDO and CDS) prepared at N/P ratio of 2 after incubation with serum	245

Figure 8.1 Hemoglobin absorption spectra obtained with 0.1 mM SA liposomes (pink), negative control (black) and positive control (green).....	250
Figure 8.2 Haemolytic Potential of SA based Cationic Liposomes.....	251
Figure 8.3 Haemolytic Potential of HDO, CDO and CDS liposomes.....	251
Figure 8.4 MTT Dye Reduction by Mitochondrial Reductase Enzyme of Viable Cells..	253
Figure 8.5 Haemocytometer diagram indicating the 16 corners squares which should be used for counting.....	257
Figure 8.6 Cytotoxicity of SA liposomes prepared without and with DOPE (SA/DOPE, SA:HSPC:Chol liposomes and SA-nonPEGylated liposomes respectively) and PEGylated SA liposomes against DOTAP/DOPE liposomes. SA/DOPE liposomes are composed of 1:1 molar ratio of SA and DOPE.....	261
Figure 8.7 Cytotoxicity of BHSA, BCSA and BASA liposomes against SA liposomes and DOTAP/DOPE liposomes	261
Figure 8.8 Cytotoxicity of HSA, CSA and ASA liposomes against SA liposomes and DOTAP/DOPE liposomes	262
Figure 8.9 Cytotoxicity of HDO, CDO and CDS liposomes against SA liposomes and DOTAP/DOPE liposomes. For comparison, control batch prepared with DSPE and DOPE without any modification was also evaluated at the same concentration range.	262
Figure 8.10 Cytotoxicity of lipoplexes prepared with SA liposomes without and with DOPE (SA/DOPE, SA:HSPC:Chol liposomes and SA-nonPEGylated liposomes respectively) and PEGylated SA liposomes against DOTAP/DOPE and lipofectamine-2000 lipoplexes. For lipofectamine-2000 lipoplexes x-axis represent, instead of N/P ratio, lipofectamine-2000 reagent volume range as per standard transfection protocol i.e. 0.4 μ L, 0.6 μ L, 0.8 μ L and 1.0 μ L. SA/DOPE lipoplexes are composed of 1:1 molar ratio of SA and DOPE.	264
Figure 8.11 Cytotoxicity of BHSA, BCSA and BASA lipoplexes against SA, DOTAP/DOPE and lipofectamine-2000 lipoplexes. For lipofectamine-2000 lipoplexes x-axis represent, instead of N/P ratio, lipofectamine-2000 reagent volume range as per standard transfection protocol i.e. 0.4 μ L, 0.6 μ L, 0.8 μ L and 1.0 μ L.....	265
Figure 8.12 Cytotoxicity of HSA, CSA and ASA lipoplexes against SA, DOTAP/DOPE and lipofectamine-2000 lipoplexes. For lipofectamine-2000 lipoplexes x-axis represent, instead of N/P ratio, lipofectamine-2000 reagent volume range as per standard transfection protocol i.e. 0.4 μ L, 0.6 μ L, 0.8 μ L and 1.0 μ L.	265

Figure 8.14 Cytotoxicity of HDO, CDO and HDS lipoplexes against SA, DOTAP/DOPE and lipofectamine-2000 lipoplexes. For lipofectamine-2000 lipoplexes x-axis represent, instead of N/P ratio, lipofectamine-2000 reagent volume range as per standard transfection protocol i.e. 0.4 μ L, 0.6 μ L, 0.8 μ L and 1.0 μ L.	266
Figure 8.15 %GFP expression observed after transfection with naked pDNA, lipoplexes of SA and Modified SA lipoplexes. Untreated cells were taken as negative control while cells treated with lipoplexes of lipofectamine-2000 were taken as a reference control for comparison.	271
Figure 8.16 Overlay histograms of FACS analyses of cellular expression of eGFP by naked pDNA, lipoplexes of SA and Modified SA lipoplexes. Untreated cells were taken as negative control while cells treated with lipoplexes of lipofectamine-2000 were taken as a reference control for comparison.	272
Figure 8.17 %GFP expression observed after transfection with naked pDNA, HDO, CDO and HDS lipoplexes. Untreated cells were taken as negative control while cells treated with lipoplexes of lipofectamine-2000 were taken as a reference control for comparison. eGFP expression by SA lipoplexes are also included for comparison.	273
Figure 8.18 Overlay histograms of FACS analyses of cellular expression of eGFP by naked pDNA, HDO, CDO and HDS lipoplexes. Untreated cells were taken as negative control while cells treated with lipoplexes of lipofectamine-2000 were taken as a reference control for comparison. Histogram of eGFP expression by SA lipoplexes are also included for comparison.	274
Figure 8.19 Confocal images of SA, BHSA and HSA lipoplexes. Cellular expression of GFP is shown for SA, BHSA and HSA lipoplexes in comparison to that after transfection done with naked eGFP pDNA, lipoplexes of DOTAP/DOPE and Lipofectamine-2000.	277
Figure 8.20 Confocal images of GFP expression after transfection with BCSA and CSA lipoplexes. Cellular expression of GFP for BCSA and CSA lipoplexes is shown in comparison to that with naked eGFP pDNA and lipoplexes of SA, DOTAP/DOPE and Lipofectamine-2000.	278
Figure 8.21 Confocal images of GFP expression after transfection with BASA and ASA lipoplexes. Cellular expression of GFP with BASA and ASA lipoplexes is shown in comparison to that with naked eGFP pDNA and lipoplexes of SA, DOTAP/DOPE and Lipofectamine-2000.	279
Figure 8.22 Confocal images of GFP expression after transfection with HDO, CDO and HDS lipoplexes. Cellular expression of GFP with HDO, CDO and CDS lipoplexes is	

shown in comparison to that with naked eGFP pDNA and lipoplexes of SA, DOTAP/DOPE and Lipofectamine-2000.	280
Figure 8.23 Calcium deposition study: Von Kossa staining of cells after transfection with different lipoplex formulations. Von Kossa stained cells 7 days after transfection with SA, BHSA, HSA, BCSA, CSA, BASA and ASA lipoplexes are shown in comparison to that with untreated cells (negative control), naked pDNA and lipoplexes of DOTAP/DOPE and Lipofectamine-2000.	284
Figure 8.24 Calcium deposition study: Von Kossa staining of cells after transfection with different lipoplex formulations. Von Kossa stained cells 7 days after transfection with SA, BHSA, HSA, BCSA, CSA, BASA and ASA lipoplexes are shown in comparison to that with untreated cells (negative control), naked pDNA and lipoplexes of DOTAP/DOPE and Lipofectamine-2000.	284
Figure 9.1 Complexation efficiency of lipoplexes before and after peptide conjugation.	288
Figure 9.2 Effect of peptide conjugation on the cytotoxicity of the lipoplexes. Cytotoxicity of targeted and non-targeted lipoplexes are shown against DOTAP/DOPE and lipofectamine-2000 lipoplexes. For lipofectamine-2000 lipoplexes x-axis represent, instead of N/P ratio, lipofectamine-2000 reagent volume range as per standard transfection protocol i.e. 0.4 μ L, 0.6 μ L, 0.8 μ L and 1.0 μ L.	290
Figure 9.3 %GFP expression observed after transfection with peptide conjugated and non-conjugated lipoplexes. Untreated cells were taken as negative control while cells treated with naked pDNA and lipoplexes of lipofectamine-2000 were taken as a reference control for comparison.	291
Figure 9.4 Confocal images of GFP expression after transfection with peptide conjugated and non-conjugated lipoplexes.	292
Figure 9.5 Calcium deposition study: Von Kossa staining of cells after transfection with different lipoplex formulations. Von Kossa stained cells 7 days after transfection with peptide conjugated and peptide non-conjugated lipoplexes are shown.	293
Figure 10.1 X-ray radiographs of the Sham operated and ovariectomized rats after 8 weeks osteoporosis induction period.	305
Figure 10.2 X-ray radiographs of the representative animals of each group: A: Sham operated, B: Vehicle control, C: Treatment I (HSA lipoplexes), D: Treatment II (HSA-	

(DSS) ₆ lipoplexes, E: Treatment III (HDS lipoplexes), F: Treatment IV (HDS-(DSS) ₆ lipoplexes	307
Figure 10.3 Effect of different formulations on the cortical bone thickness of femoral bones of the osteoporosis induced rats.....	308
Figure 10.4 Effect of different formulations on the Endosteal diameter of femoral bones of the osteoporosis induced rats	309